Beam Therapeutics Inc.

Cargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need

Beam Therapeutics sees BEAM-302 as having potential for eventual accelerated approval from the US Food and Drug Administration in alpha-1 antitrypsin deficiency (AATD) after announcing positive early

This year’s American Society of Hematology (ASH) meeting delivered positive Phase II results for a new daily oral therapy and promising interim Phase I/II data for a one-time base editing treatment fo

Beam Therapeutics reported promising efficacy in November for the first four sickle cell disease (SCD) patients treated with its base edited cell therapy BEAM-101 in the ongoing Phase I/II BEACON clin